Salesforce: My Top Long Idea For 2025

Summary:

  • Despite mixed Q3 results, CRM’s stock surged due to the launch of Agentforce, which signed 200 deals in its first week.
  • Agentforce 2.0, with advanced features and integrations, positions CRM to capitalize on the booming Enterprise AI market, projected to grow significantly.
  • Valuation suggests a 22.5% upside, with a price target of $421, driven by Agentforce’s traction and CRM’s strategic acquisitions enhancing data quality and security.
  • High stock-based compensation and potential weakening demand for Agentforce are key risks, but I maintain a Buy rating, and make CRM my top pick for 2025.

Business woman climbing to the top and reaches first place

Eoneren/E+ via Getty Images

Investment Thesis

The last time I wrote about Salesforce (NYSE:CRM) (NEOE:CRM:CA), back in July 2024, I analyzed the company’s Q1 performance and argued why the growth potential of the company’s AI tools

Forward P/E Approach

Price Target

$421.00

Projected Forward P/E Multiple

34.7

Projected FY25 EPS

$10.47

Projected PEG Ratio

2.19

FY26 Projected Earnings Growth

15.8%

Projected FY26 EPS

$12.12


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CRM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *